Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice

This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea. Patients receiving NSAIDs and requiring gastroprotective therapy will be enrolled and followed prospectively. The study will assess patient-reported outcomes (PROs) related to gastrointestinal symptoms, as well as safety outcomes.

NCT Number	NCT07558707
Lead Sponsor	Daewoong Pharmaceutical Co. LTD.
Conditions	Peptic Ulcer, NSAID-Induced Peptic Ulcer
Enrollment	7,000 participants
Start Date	2026-04-30
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-30